Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1Phase 1 1

Status

Completed 3Active not recruiting 3

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 5

Conditions

Lymphoma 225Lymphoma, Large B-Cell, Diffuse 160Small Cell Lung Carcinoma 156Precursor Cell Lymphoblastic Leukemia-Lymphoma 143Lymphoma, Non-Hodgkin 139Leukemia 135Leukemia, Myeloid, Acute 117Hodgkin Disease 106Lung Neoplasms 99Burkitt Lymphoma 99Lymphoma, Follicular 85Lymphoma, Mantle-Cell 76Lymphoma, Large-Cell, Immunoblastic 68Carcinoma, Non-Small-Cell Lung 61Neuroblastoma 60Leukemia, Lymphocytic, Chronic, B-Cell 56Recurrence 53Multiple Myeloma 52Lymphoma, B-Cell, Marginal Zone 43Congenital Abnormalities 43Sarcoma 39Central Nervous System Neoplasms 39Myelodysplastic Syndromes 35Brain Neoplasms 34Ovarian Neoplasms 32Leukemia, Myelomonocytic, Acute 32Lymphoma, B-Cell 31Leukemia, Monocytic, Acute 31Leukemia, Erythroblastic, Acute 31Testicular Neoplasms 30

Interventions

pembrolizumab 189Cisplatin 47Paclitaxel 45Carboplatin 44lenvatinib 31Docetaxel 23Pemetrexed 21Fluorouracil 20Capecitabine 17Gemcitabine 15Oxaliplatin 14Saline Solution 13Albumin-Bound Paclitaxel 11130-nm albumin-bound paclitaxel 10epacadostat 9Leucovorin 9Cetuximab 9olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6enzalutamide 5durvalumab 5belzutifan 5Nivolumab 5Dexamethasone 5Surgical Procedures, Operative 4Radiotherapy 4trifluridine tipiracil drug combination 3spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × Etoposide × Clear all
NCT04624204 2026-05-26

MK 7339-013

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
672 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT04380636 2026-05-15

MK-7339-012

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
870 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02964013 2025-10-14

KEYVIBE-001

Merck Sharp & Dohme LLC

Phase 1 Completed
474 enrolled 39 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT05298423 2025-08-01

KEYVIBE-006

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
611 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04924101 2025-07-23

KEYNOTE-B99

Merck Sharp & Dohme LLC

Phase 2 Completed
126 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT03066778 2022-10-03

KEYNOTE-604

Merck Sharp & Dohme LLC

Phase 3 Completed
453 enrolled 23 charts
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡